drugset / Trial / NCT06799637
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies. The study consists of two parts: a dose escalation part and a dose expansion part.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XNW28012 | Monoclonal antibody | 0.6 mg/kg | — |
| Subject | XNW28012 | Monoclonal antibody | 1.2 mg/kg | — |
| Subject | XNW28012 | Monoclonal antibody | 2.4 mg/kg | — |
| Subject | XNW28012 | Monoclonal antibody | 3.6 mg/kg | — |
| Subject | XNW28012 | Monoclonal antibody | 4.8 mg/kg | — |
| Subject | XNW28012 | Monoclonal antibody | 6 mg/kg | — |
| Subject | XNW28012 | Monoclonal antibody | 7.5 mg/kg | — |